Exenatide/insulin long acting - Hanmi PharmaceuticalAlternative Names: LAPSInsulin Combo; LAPSInsulin115/LAPSCA-Exendine4; HM 14220; Insulin/exenatide long-acting - Hanmi Pharmaceutical; Long-acting insulin 115/exendin-4 combination - Hanmi Pharmaceutical
Latest Information Update: 08 Nov 2015
At a glance
- Originator Hanmi Pharmaceutical
- Mechanism of Action Glucagon like peptide 1 receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Type 2 diabetes mellitus